Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Mildred Iro, a Paediatric Research Fellow working with the Oxford Vaccine Group, won the Lorber Prize for the best paediatric publication of 2017 for her work on childhood encephalitis admissions.

Mildred Iro

The winning paper, published in Lancet in April 2017, examined trends in hospital admission rates for encephalitis in children over a 33-year period (1979-2011). The results show that while hospital admission rates for all instances of childhood encephalitis in England increased between 1995 and 2011, admissions for mumps encephalitis decreased by 98%, and for measles by 97%, after the introduction of the two-dose MMR vaccination schedule. Mildred’s study is the first to quantify the effect of the MMR vaccine on childhood measles and mumps encephalitis admissions in England. It is also the first to define the incidence of all-cause childhood encephalitis in England.

Mildred Iro joined Oxford University’s Department of Paediatrics in 2012; in 2013 she commenced her DPhil at the Oxford Vaccine Group. She has done most of her paediatric training in Southampton, where she is planning to return after the completion of her doctorate to take up the position of an NIHR Academic Clinical Lecturer in Child Health and Genomics.

The Lorber Prize is given annually by the Royal College of Paediatrics and Child Health. The award honours a pre-consultant grade medical practitioner working in the UK for the best scientific paper related to paediatrics.

 

Similar stories

Preliminary data suggests mixing Covid-19 vaccine increases reactogenicity

Research, from Com-COV study comparing mixed dosing schedules of Pfizer / Oxford-AstraZeneca vaccines, shows increase in the frequency of mild-moderate symptoms in those receiving either mixed dosing schedule. Adverse reactions were short-lived, with no other safety concerns. Impact of mixed schedules on immunogenicity unknown as yet, with data to follow from this study.

Oxford vaccine professor: rich countries have a moral duty to share their COVID-19 shots

Andrew Pollard writes about vaccine equity in his article for The Conversation.

Increasing vaccine uptake among ethnic minorities

Dr Samantha Vanderslott and Dr Seilesh Kadambari discuss their collaborative approach to providing ethnic minority groups with information on vaccines.

Why we must expand newborn screening

Early diagnosis is of primary importance both to obtain the best effect of innovative medications and to accelerate their development, writes Professor Laurent Servais.

Human challenge trial launches to study immune response to COVID-19

Though the COVID-19 pandemic has now been active for a year, not much is known about what happens when people who have already had COVID-19 are infected for a second time.

Alternating vaccines trial expands to include two additional vaccines

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.